PatentsUSA
Novo Nordisk Faces Antitrust Lawsuit Over Alleged Monopoly on Victoza Diabetes Medication
Novo Nordisk has been sued for allegedly monopolizing the diabetes drug Victoza, with claims that the company engaged in anticompetitive practices to maintain exclusive control over the market. The lawsuit highlights concerns about market dominance and access to essential diabetes treatments.
Friday, January 23, 2026